(Q37827399)

23 August 2017

1 reference

title

Angiogenesis and invasion in glioma (English)

1 reference

23 August 2017

1 reference

Manabu Onishi

1

1 reference

23 August 2017

Tomotsugu Ichikawa

series ordinal

2

1 reference

23 August 2017

Kazuhiko Kurozumi

series ordinal

3

1 reference

23 August 2017

Isao Date

series ordinal

4

1 reference

23 August 2017

publication date

8 January 2011

1 reference

23 August 2017

published in

Brain Tumor Pathology

1 reference

23 August 2017

volume

28

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

13-24

1 reference

https://scigraph.springernature.com/pub.10.1007/s10014-010-0007-z

23 August 2017

exact match

0 references

cites work

The WHO classification of tumors of the nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiogenesis in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiogenesis in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Pathology and molecular genetics of astrocytic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

21 January 2018

Angiogenesis in gliomas.

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiogenesis in brain tumors; pathobiological and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Topographic anatomy and CT correlations in the untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiogenesis-independent tumor growth mediated by stem-like cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Biology of angiogenesis and invasion in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

The role of pericytes in blood-vessel formation and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

The role of angiopoietins during angiogenesis in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Proteases and glioma angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Requirement of vascular integrin alpha v beta 3 for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

HIF hydroxylation and the mammalian oxygen-sensing pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Hypoxia: the tumor's gateway to progression along the angiogenic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Molecular regulation of vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Molecular mechanisms of glioma cell migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Glioma migration: clues from the biology of neural progenitor cells and embryonic CNS cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Influence of in vitro systems on embryo survival and fetal development in cattle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Connexins, connexons, and intercellular communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Gap junctions in the brain: where, what type, how many and why?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Gap junction intercellular communication in gliomas is inversely related to cell motility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Reduced expression of connexin-43 and functional gap junction coupling in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Mechanism and biological significance of CD44 cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

CD44s-targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Regulated CD44 cleavage under the control of protein kinase C, calcium influx, and the Rho family of small G proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Metastatic potential correlates with enzymatic degradation of basement membrane collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Molecular determinants of glioma cell migration and invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

The role of myosin II in glioma invasion of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

MSAP enhances migration of C6 glioma cells through phosphorylation of the myosin regulatory light chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Expression of hypoxia-inducible factor 1? in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Molecularly targeted therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Sorafenib exerts anti-glioma activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-010-0007-Z

10.1007/S10014-010-0007-Z

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference